Magic-Mushrooms.net

Psilocybin is absorbed through the lining of the mouth and stomach. Effects begin 1040 minutes after ingestion of psilocybin-containing mushrooms, and last from 26 hours depending on dose, species, and individual metabolism.[11] A typical recreational dosage is from 1050 mg psilocybin. The effects of psilocybin are highly variable, and dependent on the current mood and overall sense of well-being by the individual. Initially the subject may begin to feel somewhat disorientated, lethargic, and euphoric or sometimes depressed. At low doses, hallucinatory effects may occur, including enhancement of colors and the animation of geometric shapes. Closed-eye visuals may occur, where the affected individual may see multi-coloured geometric shapes and vivid imaginative sequences. At higher doses, hallucinatory effects increase and experiences tend to be less social and more introspectic or entheogenic. Open-eye visuals are more common, and may be very detailed although rarely confused with reality. Users having a pleasant experience may feel ecstatic, including a deep sense of connection to others, confusion, hilarity, and a general feeling of connection to nature and the universe. Difficult experiences or bad trips may occur in some individuals, often when consumed during emotional turmoil, in a non-supportive or inadequate environment, by an inexperienced person, or in an unexpectedly high dose (see: set and setting). Latent psychological issues may be triggered by the strong emotional components of the experience. [12] Some of these individuals report that they have experienced a ‘spiritual’ episode. For example, in the Marsh Chapel Experiment, which was run by a graduate student at Harvard Divinity School under the supervision of Timothy Leary, almost all of the graduate degree divinity student volunteers who received psilocybin reported profound religious experiences. A brief video about the Marsh Chapel experiment can be viewed here. In 2006, a group of researchers from Johns Hopkins School of Medicine led by Roland R Griffiths conducted an experiment assessing the degree of mystical experience and attitudinal effects of the psilocybin experience; this report was published in the journal Psychopharmacology. Thirty-six volunteers without prior experience with hallucinogens were given psilocybin and methylphenidate (Ritalin) in separate sessions, the methylphenidate sessions serving as a control and psychoactive placebo; the tests were double-blind. The degree of mystical experience was measured using a questionnaire on mystical experience developed by Ralph W Hood; 61% of subjects reported a “complete mystical experience” after their psilocybin session, while only 13% reported such an outcome after their experience with methylphenidate. Two months after taking psilocybin, 79% of the participants reported moderately to greatly increased life satisfaction and sense of well-being. About 36% of participants also had a strong to extreme experience of fear or dysphoria (i.e., a bad trip) at some point during the psilocybin session (which was not reported by any subject during the methylphenidate session), with about one-third of these (13% of the total) reporting that this dysphoria dominated the entire session. These negative effects were reported to be easily managed by the researchers and did not have a lasting negative effect on the subjects sense of well-being.[13] Further measures at 14 months after the psilocybin experience confirmed that participants continued to attribute deep personal meaning to the experience. This research was widely covered in the major media outlets.[14] The research team cautions that if hallucinogens are used in less well supervised settings, the possible fear or anxiety responses could lead to harmful behaviors.[15] Further studies by this group are investigating the relationship of psilocybin dose to likelihood of mystical experience in healthy volunteers[citation needed] and whether mystical experiences in volunteers given psilocybin can help with anxiety and poor mood due to cancer.[16] . Individual brain chemistry and metabolism plays a large role in determining a person’s response to psilocybin. Psilocybin is metabolized mostly in the liver where it becomes psilocin. It is broken down by the enzyme monoamine oxidase. MAO inhibitors have been known to sustain the effects of psilocybin for longer periods of time; people who are taking an MAOI for a medical condition or are seeking to potentiate the mushroom experience may experience highly potentiated effects. Mental and physical tolerance to psilocybin builds and dissipates quickly. Taking psilocybin more than three or four times in a week (especially on consecutive days) can result in diminished effects. Tolerance dissipates after a few days, so frequent users often keep doses spaced five to seven days apart to avoid the effect.

In the year 1560, the Spanish priest Bernardino de Sahagún wrote about the use of peyote and magic mushrooms by the Aztecs in his Florentine Codex. He estimated that peyote had been in use by the native people since at least 300 BC.

The Galerina branch of mushrooms have three species which are deadly and very poisonous when ingested. Similarly, Conocybe filaris are extremely poisonous mushrooms. These four specific kinds of mushrooms are commonly found in mulched gardens in the Pacific Northwest of the United States and other regions of the world, and have been observed sharing the same habitat as the magic mushrooms Psilocybe stuntzii, Psilocybe baeocystis and the more popular Psilocybe cyanescens.